Targeting netrin‐3 in small cell lung cancer and neuroblastoma

Targeting netrin‐3 in small cell lung cancer and neuroblastoma

Abstract The navigation cue netrin‐1 is well‐documented for its key role in cancer development and represents a promising therapeutic target currently under clinical investigation. Phase 1 and 2 clinical trials are ongoing with NP137, a humanized monoclonal antibody against netrin‐1. Interestingly,...

Full description

Bibliographic Details
Main Authors: Shan Jiang, Mathieu Richaud, Pauline Vieugué, Nicolas Rama, Jean‐Guy Delcros, Maha Siouda, Mitsuaki Sanada, Anna‐Rita Redavid, Benjamin Ducarouge, Maëva Hervieu, Silvia Breusa, Ambroise Manceau, Charles‐Henry Gattolliat, Nicolas Gadot, Valérie Combaret, David Neves, Sandra Ortiz‐Cuaran, Pierre Saintigny, Olivier Meurette, Thomas Walter, Isabelle Janoueix‐Lerosey, Paul Hofman, Peter Mulligan, David Goldshneider, Patrick Mehlen, Benjamin Gibert
Format: Article
Language:English
Published: Springer Nature 2021-03-01
Series:EMBO Molecular Medicine
Subjects:
axon guidance
netrin‐1
netrin‐3
neuroblastoma
small cell lung cancer
Online Access:https://doi.org/10.15252/emmm.202012878

Internet

https://doi.org/10.15252/emmm.202012878

Similar Items